ResearchHub | Open Science Community

Meng Li

Author with expertise in Efficacy and Resistance in CML Treatment

Achievements

This user has not unlocked any achievements yet.

Key Stats

Upvotes received:

Publications:

(0% Open Access)

Cited by:

h-index:

i10-index:

Reputation

Biology

< 1%

Chemistry

< 1%

Economics

< 1%

How is this calculated?

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis